Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ATHA 
Athira Pharma Inc (ATHA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: ATHA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0.5
1 Year Target Price $0.5
| 0 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 44% | Avg. Invested days 42 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 15.15M USD | Price to earnings Ratio - | 1Y Target Price 0.5 |
Price to earnings Ratio - | 1Y Target Price 0.5 | ||
Volume (30-day avg) 3 | Beta 3.02 | 52 Weeks Range 0.22 - 0.83 | Updated Date 09/16/2025 |
52 Weeks Range 0.22 - 0.83 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.64 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -49.29% | Return on Equity (TTM) -103.8% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -14607843 | Price to Sales(TTM) - |
Enterprise Value -14607843 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.31 | Shares Outstanding 39439300 | Shares Floating 25302694 |
Shares Outstanding 39439300 | Shares Floating 25302694 | ||
Percent Insiders 8.7 | Percent Institutions 45.04 |
Upturn AI SWOT
Athira Pharma Inc
Company Overview
History and Background
Athira Pharma, Inc. (ATHA) is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Founded in 2011, it has focused on developing disease-modifying therapies for Alzheimer's and other neurodegenerative diseases.
Core Business Areas
- Neurodegenerative Disease Therapies: Focuses on developing therapies targeting the HGF/MET pathway to promote neuroprotection and improve cognitive function in neurodegenerative diseases like Alzheimer's.
Leadership and Structure
Athira Pharma is led by a management team with experience in drug development and neuroscience. The organizational structure includes research, development, clinical, and commercial teams.
Top Products and Market Share
Key Offerings
- Fosgonimeton: Fosgonimeton is Athira's lead investigational product candidate for the treatment of Alzheimer's disease and other dementias. Market share is currently 0 as it is still in development. Competitors include companies developing other Alzheimer's drugs like Eisai (LEMYBI) and Eli Lilly (donanemab).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and innovative, with significant investments in research and development. The Alzheimer's disease market is large and growing due to the aging population.
Positioning
Athira Pharma is a clinical-stage company focused on developing novel therapeutics for neurodegenerative diseases. It aims to differentiate itself through its focus on the HGF/MET pathway.
Total Addressable Market (TAM)
The global Alzheimer's disease market is expected to reach hundreds of billions of dollars. Athira Pharma aims to capture a significant portion of this market with successful development and commercialization of its therapies.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach targeting the HGF/MET pathway
- Potential for disease-modifying therapies for Alzheimer's
- Strong intellectual property position
- Experienced management team
Weaknesses
- Clinical-stage company with no approved products
- Dependence on successful clinical trial outcomes
- High cash burn rate
- Past data integrity issues raised questions with lead candidate
Opportunities
- Growing market for Alzheimer's disease therapies
- Potential for strategic partnerships with larger pharmaceutical companies
- Expansion of pipeline into other neurodegenerative diseases
- Positive clinical trial results could lead to significant stock price appreciation
Threats
- Clinical trial failures
- Regulatory hurdles and delays
- Competition from other Alzheimer's disease therapies
- Generic erosion of existing therapies
Competitors and Market Share
Key Competitors
- LLY
- ESAI
- ABBV
Competitive Landscape
Athira Pharma faces competition from established pharmaceutical companies with greater resources and approved products. Its competitive advantage lies in its novel approach to treating neurodegenerative diseases.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited as Athira Pharma is primarily focused on R&D.
Future Projections: Future growth depends on the successful development and commercialization of its pipeline. Analyst estimates vary widely based on clinical trial outcomes.
Recent Initiatives: Recent initiatives include advancing clinical trials of Fosgonimeton and exploring new indications.
Summary
Athira Pharma is a risky, clinical-stage company that hinges on positive clinical trial results for its lead drug candidate, fosgonimeton. Its novel approach to Alzheimer's treatment provides potential, but it faces strong competition from larger, established players. ATHA has faced several issues with data integrity in the past. Success in its upcoming clinical trials is paramount for its future.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The biotechnology industry is inherently risky, and investment decisions should be made after careful consideration of individual circumstances.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Athira Pharma Inc
Exchange NASDAQ | Headquaters Bothell, WA, United States | ||
IPO Launch date 2020-09-18 | President, CEO & Director Dr. Mark J. Litton M.B.A., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 26 | Website https://www.athira.com |
Full time employees 26 | Website https://www.athira.com | ||
Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.